



OPEN ACCESS

Identifying occupational carcinogens: an update from the IARC Monographs

Dana Loomis, Neela Guha, Amy L Hall, Kurt Straif

IARC Monographs Programme,
International Agency for
Research on Cancer, Lyon,
France

Correspondence to
Professor Dana Loomis,
International Agency for
Research on Cancer, Lyon
69372, France;
dploomis@unr.edu

Received 6 December 2017
Revised 6 April 2018
Accepted 9 April 2018
Published Online First
16 May 2018

ABSTRACT

The recognition of occupational carcinogens is important for primary prevention, compensation and surveillance of exposed workers, as well as identifying causes of cancer in the general population. This study updates previously published lists of known occupational carcinogens while providing additional information on cancer type, exposure scenarios and routes, and discussing trends in the identification of carcinogens over time. Data were extracted from International Agency for Research on Cancer (IARC) Monographs covering the years 1971–2017, using specific criteria to ensure occupational relevance and provide high confidence in the causality of observed exposure-disease associations. Selected agents were substances, mixtures or types of radiation classified in IARC Group 1 with 'sufficient evidence of carcinogenicity' in humans from studies of exposed workers and evidence of occupational exposure documented in the pertinent monograph. The number of known occupational carcinogens has increased over time: 47 agents were identified as known occupational carcinogens in 2017 compared with 28 in 2004. These estimates are conservative and likely underestimate the number of carcinogenic agents present in workplaces. Exposure to these agents causes a wide range of cancers; cancers of the lung and other respiratory sites, followed by skin, account for the largest proportion. The dominant routes of exposure are inhalation and dermal contact. Important progress has been made in identifying occupational carcinogens; nevertheless, there is an ongoing need for research on the causes of work-related cancer. Most workplace exposures have not been evaluated for their carcinogenic potential due to inadequate epidemiologic evidence and a paucity of quantitative exposure data.

INTRODUCTION

Historically, much of what was known about the causes of cancer was derived from studies of workers. Indeed, an observant 18th-century physician's conclusion that cancer of the scrotum in young chimney sweeps was caused by their occupational exposure to soot, later found to contain polycyclic aromatic hydrocarbons,¹² is often cited as the first clear identification of a carcinogen (eg, refs 3 4). With the notable exception of tobacco smoking, most of the other carcinogens that were recognised during the 19th to mid-20th centuries were discovered through similar observations.⁵ Even after several decades of intensive research beginning in the mid-20th century, nearly half of the 'established human carcinogens' listed in Doll and Peto's seminal report on the avoidable causes of cancer were occupational in nature.³ These discoveries

have been facilitated by characteristics of the work environment that allow cancer occurrence to be studied, notably well-defined populations that are exposed, often at high levels, to agents that can be quantitatively characterised. Analytical methods first developed to study occupational cancer have also contributed importantly to the development of modern epidemiology.⁶

Identifying occupational carcinogens is an important research endeavour with broad relevance to science and public health. Occupational exposure to carcinogens is a major cause of death and disability worldwide,⁷ with an estimated occurrence of 666 000 fatal work-related cancers annually.⁸ Knowledge of cancer hazards from occupational exposure supports prevention and surveillance activities, as well as compensation of exposed workers. However, creating a list of occupational carcinogens is not a trivial exercise, as there is neither a consensus definition of such agents nor a single, definitive source of all the relevant data. Doll and Peto³ provided a table of 'established occupational causes of cancer,' but did not specify the methodology by which they were identified. Some 20 years later, Siemiatycki and coauthors⁹ developed a list of 'definite occupational carcinogens', drawing on data from the *IARC Monographs on Carcinogenic Risks to Humans* published through 2003 and other sources. The International Agency for Research on Cancer (IARC) Monographs have been updated since then: more than 120 additional agents have been evaluated in 36 new volumes; furthermore, the methodology for evaluating the evidence base has been updated,^{10 11} and a re-evaluation of the agents classified as 'carcinogenic to humans' in the first 99 volumes has been completed with additional target organ sites identified in the process.¹²

Here we provide an updated listing of occupational carcinogens that includes data through volume 120 of the IARC Monographs corresponding to the years 1971–2017. We also provide additional information on tumour type, exposure scenarios and exposure routes, identify methodological challenges in compiling such a list from available data sources, and discuss trends in the identification of carcinogens over time.

METHODS

As a primary source of data, we used the *IARC Monographs on Carcinogenic Risks to Humans*, the world's most comprehensive encyclopaedia of evaluations of carcinogenicity, comprising over 1000 entries.¹³ The review and evaluation methods used to develop the IARC Monographs are documented in the *IARC Monographs Preamble*.¹⁰



► <http://dx.doi.org/10.1136/oemed-2018-105189>



To cite: Loomis D,
Guha N, Hall AL, et al.
Occup Environ Med
2018;**75**:593–603.

Briefly, agents are selected for review based on evidence of human exposure and published scientific data suggestive of carcinogenicity. For each agent evaluated, systematic reviews of the available scientific evidence concerning the carcinogenicity of the agent in humans and experimental animals are conducted by an international working group of independent experts. Each line of evidence is evaluated according to ordered categories that reflect the strength of the evidence of carcinogenicity. The highest category of 'sufficient evidence of carcinogenicity' in humans or animals means that a causal relationship between exposure to the agent and development of cancer has been established. For epidemiological data, 'sufficient evidence of carcinogenicity' is typically based on results from several well-designed, well-conducted studies where chance, bias and confounding could be ruled out with reasonable confidence; the conclusion is unlikely to be altered by future studies. Data on human exposure to the agent and toxicological data on pertinent mechanisms of carcinogenesis are also reviewed.

An overall evaluation integrating epidemiological and experimental data is derived according to a structured process that accounts for the strength of evidence for carcinogenicity in humans, animals and mechanistic evidence, most notably in exposed humans. Agents with 'sufficient evidence of carcinogenicity' in humans are assigned by default to the highest category, 'carcinogenic to humans' (IARC Group 1) whereas the categories of 'probably' (Group 2A) or 'possibly' (Group 2B) carcinogenic to humans, or 'not classifiable as to its carcinogenicity to humans' (Group 3) are assigned according to the combined strength of the human, animal and mechanistic evidence. Evaluations may be upgraded to a higher category when the evidence for a relevant mechanism of carcinogenesis is sufficiently strong. From the initiation of the IARC Monographs programme in 1971 to date, 119 agents have been classified in Group 1, 81 in Group 2A and 299 in Group 2B. These classifications refer to the strength of the evidence for a cancer hazard, rather than to the level of cancer risk.

Definitions

In the absence of a consensus definition of an occupational carcinogen, we developed the following criteria:

1. The agent is a defined substance, a mixture, or a type or source of radiation.
2. The agent is classified in IARC Group 1 with 'sufficient evidence of carcinogenicity' in humans (to ensure that observed exposure-disease associations are causal).
3. 'Sufficient evidence of carcinogenicity' in humans is obtained entirely or in part from epidemiologic studies of exposed workers (to ensure that the carcinogen has documented occupational exposure); the occurrence of exposure in workers is documented in the pertinent monograph.

Evaluations based on an occupational title, industry or production process without specification of causal agents were also recorded, but were considered separately since they are qualitatively different from the other classes of agents and afford limited opportunities for prevention. Furthermore, such evaluations are time sensitive given that processes, materials and exposures change over time. Infectious agents and pharmaceutical preparations, including botanicals, hormones and antineoplastic agents, were effectively excluded because the pertinent monographs did not provide information indicating occupational exposure. These exclusions also facilitate comparison with previous reviews by Doll and Peto³ and Siemiatycki *et al.*⁹

Review and data extraction

Two of us (NG and DL) independently reviewed data for all of the 120 agents classified in Group 1 through October 2017 in volumes 1–120 of the IARC Monographs to identify entries that met the criteria defined above. These determinations were reviewed by a third person (KS) and any discrepancies were resolved by discussion. For each included agent, we extracted data on the cancer sites for which the human evidence was classified as sufficient, where the classification was established on the basis of epidemiologic studies of workers, and where the occurrence of exposure in workers was documented in the monograph.

We also summarised agents across six broad classes adapted from Coglianò *et al.*¹²: chemicals; chemical mixtures; metals and metal compounds; airborne particles; airborne complex mixtures, and radiation and radionuclides. We grouped arsenic with the metals, although it is now considered to be a metalloid, to avoid creating of class containing a single agent.

Information on settings where occupational exposure is likely to occur, as described in the pertinent monograph, was extracted. Primary routes of exposure were also recorded for agents in categories other than radiation and radionuclides. If the monograph did not provide this information, we consulted other sources, most often the NIOSH Pocket Guide to Chemical Hazards.¹⁴

RESULTS AND DISCUSSION

Counting occupational carcinogens

Among the 120 agents classified in IARC Group 1, 70 included mention of occupational exposures in the monographs (figure 1). Of these 70 Group 1 agents, 63 had sufficient evidence in humans (figure 1). The other seven had indications of occupational exposure but had been upgraded to Group 1 based on mechanistic evidence when the human evidence was less than 'sufficient'. These agents were therefore excluded from our count of occupational carcinogens: ethylene oxide, dyes metabolised to benzidine, neutron radiation, benzo(a)pyrene, 2,3,4,7,8-pentachlorodibenzofuran, 4,4'-methylenebis(2-chloroaniline) and dioxin-like polychlorinated biphenyls.

Of the 63 Group 1 agents with 'sufficient evidence of carcinogenicity' in humans, 59 evaluations were based at least in part on studies of exposed workers (figure 1). The other four agents (aflatoxins, the asbestos-like fibres erionite and fluoroedenite and fission products including Strontium-90) were excluded since occurrence of occupational exposure was noted but no occupational epidemiology data were reported.

Among these 59 retained agents, 47 were individual substances, mixtures or types of radiation and 12 were occupations, industries or processes (figure 1). Although the IARC Monographs aim to identify and evaluate specific agents, some processes, industries and occupations have been classified in Group 1 with 'sufficient evidence of carcinogenicity' in humans (table 1). These evaluations were typically produced at a time when the available data provided a clear indication of increased cancer risk in an occupational group, but not enough information to identify a causal agent. While such broadly defined carcinogenic agents can lead to general industrial hygiene interventions, provide support to compensate exposed workers and stimulate research to identify specific causes, they have limited utility for informing specific prevention activities and may be affected by changes in processes, materials and exposure levels over time.




Figure 1 Defining occupational carcinogens from the International Agency for Research on Cancer (IARC) Monographs (1971–2017).

The 47 specific substances, mixtures and types of radiation defined as occupational carcinogens are listed in [table 2](#), with the cancer sites for which sufficient evidence was obtained.

Our working definition of an occupational carcinogen was developed with high specificity to ensure confidence that the observed associations between exposure and cancer were causal

Table 1 Group 1 agents evaluated in the IARC Monographs Volumes 1–120, excluded from primary list of occupational carcinogens

| Agent | Volume (a) | Year (a) | Cancers with sufficient evidence in humans (b) |
|--|------------|----------|---|
| <i>Reason for Exclusion: Group 1 classification based on mechanistic upgrade</i> | | | |
| Ethylene oxide | 60 | 1994 | N/A |
| 2,3,4,7,8-Pentachlorodibenzofuran | 100F | 2012 | N/A |
| 3,4,5,3',4'-Pentachlorobiphenyl (PCB-126) | 100F | 2012 | N/A |
| 4,4'-Methylenebis(2-chloroaniline) (MOCA) | 99 | 2010 | N/A |
| Benzidine, dyes metabolized to | 99 | 2010 | N/A |
| Benzo(a)pyrene | 92 | 2010 | N/A |
| Neutron radiation | 75 | 2000 | N/A |
| <i>Reason for Exclusion: Evaluation did not include occupational epidemiology data</i> | | | |
| Aflatoxins | Sup 7 | 1987 | Liver |
| Erionite | Sup 7 | 1987 | Mesothelioma |
| Fission products, including strontium-90 | 100D | 2012 | Salivary gland, oesophagus, stomach, colon, lung, bone, basal cell of the skin, female breast, kidney, urinary bladder, brain and CNS, thyroid, leukaemia |
| Fluoro-edenite fibrous amphibole | 111 | 2017 | Mesothelioma |
| <i>Reason for Exclusion: Group 1 classification is for an occupation, industry, or process</i> | | | |
| Acheson process, occupational exposure associated with | 111 | 2017 | Lung |
| Aluminium production | Sup 7 | 1987 | Lung, bladder |
| Auramine production | Sup 7 | 1987 | Bladder |
| Coal gasification | Sup 7 | 1987 | Lung |
| Coal-tar distillation | 92 | 2010 | Skin |
| Coke production | Sup 7 | 1987 | Lung |
| Haematite mining (underground, with exposure to radon)(c) | Sup 7 | 1987 | Lung |
| Iron and steel founding (occupational exposure during) | Sup 7 | 1987 | Lung |
| Isopropyl alcohol manufacture using strong acids | Sup 7 | 1987 | Nasal cavity |
| Magenta production | Sup 7 | 1987 | Bladder |
| Painter (occupational exposure as a) | 47 | 1989 | Lung, mesothelioma, bladder |
| Rubber manufacturing industry (occupational exposures in) | Sup 7 | 1987 | Leukaemia, lymphoma, lung, stomach, bladder |

Table 2 Occupational carcinogens evaluated in the IARC Monographs volumes 1–120 and comparison with two previous published listings

| Agent | Volumet | Year† | Primary exposure routes‡ | | | Human cancers with sufficient evidence§ | Quantitative exposure-response data available | Included in Siemiatycki <i>et al</i> [¶] | Included in Doll and Peto ³ | Occupational exposure settings¶¶ | Class |
|--|---------|-------|--------------------------|------------|----------------|---|---|---|---|----------------------------------|-------|
| | | | Ingestion | Inhalation | Dermal contact | | | | | | |
| 1,2-Dichloropropane | 110 | 2017 | | x | | Biliary tract | | | Manufacture of plastic products, paints and other chemicals; printing; car painting | Chemicals | |
| 1,3-Butadiene | 97 | 2008 | x | | | Haematolymphatic organs | x | | Manufacture of industrial chemicals, rubber products and plastic products; petroleum refining and petrochemical industries; building construction | Chemicals | |
| 2-Naphthylamine | 4 | 1973 | x | x | x | Urinary bladder | x | x | Manufacture of industrial chemicals and dyes | Chemicals | |
| 2,3,7,8-Tetrachlorodibenzo- <i>para</i> -dioxin | 69 | 1997 | x | x | x | All cancers combined | x | x | Manufacture of chemicals; herbicide handling and spraying; waste incineration | Chemicals | |
| 4-Aminobiphenyl | 1 | 1972 | x | x | x | Urinary bladder | x | x | Manufacture of chemicals and rubber | Chemicals | |
| Acid mists, strong inorganic | 54 | 1992 | x | x | x | Larynx | x | | Manufacture of soaps and detergents, phosphate fertilisers, lead batteries and other chemicals; electroplating and pickling | Airborne particles | |
| Arsenic and inorganic arsenic compound‡ | 2 | 1973 | x | x | x | Lung, skin, bladder | x | x | Manufacture of glass, pesticides and other chemicals; agricultural settings; mining, smelting and refining of metals; medical and veterinary procedures | Metals and metal compounds | |
| Asbestos (all forms, including actinolite, amosite, anthophyllite, chrysotile, crocidolite, tremolite) | 2 | 1973 | x | x | x | Lung, mesothelioma, larynx, ovary | x | x | Mining, processing, transportation and handling of asbestos; work in shipyards; manufacture and use of asbestos-containing products | Airborne particles | |
| Benzene | 7 | 1974 | x | x | x | Leukaemia (acute myeloid) | x | x | Manufacture and use of paints, rubber products, glues and other chemicals; distribution and handling of petrol; shoe manufacturing and repair | Chemicals | |
| Benzidine | 1 | 1971 | x | x | x | Bladder | x | x | Manufacture of chemicals, dyes, rubbers and plastics | Chemicals | |

continued

Table 2 continued

| Agent | Volumet | Year† | Primary exposure routes† | | | | Human cancers with sufficient evidences‡ | Quantitative exposure-response data available | Included in Siemiatycki <i>et al</i> ‡ | Included in Doll and Peto ³ | Occupational exposure settings¶ | Class |
|---|---------|-------|--------------------------|------------|----------------|----------------------------------|--|---|--|---|---------------------------------|-------|
| | | | Ingestion | Inhalation | Dermal contact | | | | | | | |
| Beryllium and beryllium compounds | 58 | 1993 | x | x | x | Lung | x | x | | Beryllium extraction, processing and fabrication; manufacture of electrical equipment, electronic components, aerospace materials; dental laboratory procedures | Metals and metal compounds | |
| Bis(chloromethyl)ether; chloromethyl methyl ether (technical grade) | 4 | 1974 | x | | | Lung | | x | Yes | Manufacture of chemicals; laboratory procedures | Chemicals | |
| Cadmium and cadmium compounds | 58 | 1993 | x | x | | Lung | x | x | | Production, refining, and processing of cadmium and its alloys; manufacture of batteries and pigments | Metals and metal compounds | |
| Chromium (VI) compounds | Sup 7 | 1987 | x | | | Lung | x | x | Yes | Production and use of chromate pigments and paints; chrome plating; work in chrome-alloy foundries | Metals and metal compounds | |
| Coal-tar pitch | 35 | 1985 | x | x | x | Lung, skin | | x | | Production of coal-tar products; roofing and surface coating activities | Chemical mixtures | |
| Engine exhaust, diesel | 105 | 2013 | x | | | Lung | x | | | Rail, truck, and bus operation and mechanical maintenance; mining; firefighting | Airborne complex mixtures | |
| Formaldehyde | 88 | 2006 | x | x | x | Nasopharynx, leukaemia | x | | | Manufacture of formaldehyde and other chemicals; histopathology and anatomy dissections; hospital disinfection; embalming | Chemicals | |
| Ionising radiation (all types)** | 100D | 2012 | | | | None specified | x | x | x | Outdoor work involving sun exposure; nuclear fuel production and use; air travel; mining; human and veterinary medicine | Radiation and radionuclides | |
| Leather dust | 25 | 1981 | x | | | Nasal cavity and paranasal sinus | | | | Manufacture, processing and repair of leather; boots and shoes | Airborne particles | |
| Lindane (see also hexachlorocyclohexanes) | 113 | 2015* | x | x | x | Non-Hodgkin's lymphoma | x | | | Manufacture of lindane; treatment of wood and wooden structures; agricultural application on livestock and crops | Chemicals | |

continued

Table 2 continued

| Agent | Volumet | Year† | Primary exposure routes† | | | Human cancers with sufficient evidence§ | Quantitative exposure-response data available | Included in Siemiatycki <i>et al</i> ⁶ | Included in Doll and Peto ³ | Occupational exposure settings¶ | Class |
|--|---------|-------|--------------------------|------------|----------------|--|---|---|---|---------------------------------|-------|
| | | | Ingestion | Inhalation | Dermal contact | | | | | | |
| Mineral oils, untreated or mildly treated | 3 | 1973 | | x | x | Skin | x | | Paraffin processing; manufacture of metal products; metal working | Chemical mixtures | |
| Nickel compounds | 49 | 1990 | x | x | x | Lung, nasal cavity and paranasal sinuses | x | x | Mining, smelting and refining of nickel; production of nickel alloys; stainless steel and batteries; electroplating; paint production and use | Metals and metal compounds | |
| <i>ortho</i> -Toluidine | 99 | 2010 | | x | x | Urinary bladder | | | Manufacture of <i>ortho</i> -toluidine and dyes, pigments, and some rubber chemicals; clinical and pathological laboratories | Chemicals | |
| Outdoor air pollution** | 109 | 2016 | | x | | Lung | x | | Where majority of working time is spent in polluted outdoor environments | Airborne particles | |
| Particulate matter in outdoor air pollution | 109 | 2016 | | x | | Lung | x | | (eg, urban traffic police, professional drivers, street vendors) | Airborne particles | |
| Pentachlorophenol | 117 | 2016* | | x | x | Non-Hodgkin's lymphoma | x | | Manufacture of PCP and other chemicals; agricultural settings; treatment of wood products; waste incineration | Chemicals | |
| Plutonium | 78 | 2001 | | | | Bone, liver, lung | x | | Nuclear industry workers | Radiation and radionuclides | |
| Polychlorinated biphenyls | 107 | 2016 | | x | x | Malignant melanoma | x | | Manufacture of PCB capacitors; manufacture and repair of transformers; waste incineration and recycling; firefighting | Chemical mixtures | |
| Radioiodines, including iodine-131†† | 78 | 2001 | | | | Thyroid | x | | Workers involved in nuclear accident clean-up | Radiation and radionuclides | |
| Radionuclides, alpha-particle emitting, internally deposited** | 78 | 2001 | | | | None specified | x | | Mining and processing of uranium and other minerals; nuclear industry workers; human and veterinary medicine | Radiation and radionuclides | |
| Radionuclides, beta-particle emitting, internally deposited** | 78 | 2001 | | | | None specified | x | | | Radiation and radionuclides | |
| Radium-224 and its decay products§ | 78 | 2001 | | | | Bone | | | Luminising industries | Radiation and radionuclides | |
| Radium-226 and its decay products | 78 | 2001 | | | | Bone, mastoid process, paranasal sinus | | | | Radiation and radionuclides | |
| Radium-228 and its decay products | 78 | 2001 | | | | Bone, mastoid process, paranasal sinus | | | | Radiation and radionuclides | |

continued

Table 2 continued

| Agent | Volumet | Year† | Primary exposure routes† | | | Human cancers with sufficient evidences‡ | Quantitative exposure-response data available | Included in Siemiatycki <i>et al</i> ⁶ | Included in Doll and Peto ³ | Occupational exposure settings¶ | Class |
|---|---------|-------|--------------------------|------------|----------------|--|---|---|---|---------------------------------|-------|
| | | | Ingestion | Inhalation | Dermal contact | | | | | | |
| Radon-222 and its decay products | 43 | 1988 | | | | Lung | x | | Mining and other underground work; mineral processing | Radiation and radionuclides | |
| Shale oils | 35 | 1985 | | | x | Skin | | x | Mining and production of shale oils and products; manufacturing of cotton textiles | Chemical mixtures | |
| Silica dust, crystalline, in the form of quartz or cristobalite | 68 | 1997 | x | | | Lung | x | x | Mining and quarrying operations; foundries; ceramics, cement and glass industries; construction activities | Airborne particles | |
| Solar radiation** | 55 | 1992 | | | | Skin (basal cell carcinoma, squamous cell carcinoma, melanoma) | x | | Outdoor work with sun exposure | Radiation and radionuclides | |
| Soot | 3 | 1973 | | x | x | Lung, skin | | x | Industries and tasks with exposure to combustion products (eg, coke-making, chimney cleaning, incineration) | Airborne particles | |
| Sulfur mustard (see also mustard gas) | 9 | 1975 | x | | | Lung | | x | Manufacture of mustard gas; military service in WWI | Chemicals | |
| Tobacco smoke, secondhand** | 83 | 2004 | x | | | Lung | | | Work in public settings where smoking occurs (eg, restaurants, bars, casinos, planes) | Airborne complex mixtures | |
| Trichloroethylene | 106 | 2014 | | x | x | Kidney | | | Manufacture of metals and plastic products; printing; textile furnishing; dry cleaning; construction | Chemicals | |
| Ultraviolet radiation** | 118 | 2017* | | | | Eye, skin | x | x | Various work environments where welding is performed | Radiation and radionuclides | |
| Vinyl chloride | 7 | 1974 | | x | | Liver (angiosarcoma, hepatocellular carcinoma) | x | x | Manufacture of polyvinyl chloride | Chemicals | |
| Welding fumes | 118 | 2017* | | x | | Lung | x | | Various work environments where welding is performed | Airborne particles | |
| Wood dust | 62 | 1995 | | x | | Nasal cavity and paranasal sinus, nasopharynx | x | x | Forestry and logging; sawmilling; manufacture of wood products; carpentry; construction | Airborne particles | |

continued

Table 2 continued

| Agent | Primary exposure routes† | | | Human cancers with sufficient evidence‡ | Quantitative exposure-response data available | Included in Siemiatycki <i>et al</i> ⁶ | Included in Doll and Peto ³ | Occupational exposure settings¶ | Class |
|-----------------------------------|--------------------------|------------|----------------|--|---|---|--|--|-----------------------------|
| | Ingestion | Inhalation | Dermal contact | | | | | | |
| X-radiation and gamma-radiation** | Volume‡ | Year† | 2000 | Multiple, including: breast; leukaemia; thyroid; bone; brain and central nervous system; colon; kidney; lung; oesophagus; salivary gland; skin; stomach; bladder | x | | | Nuclear industry workers; human and veterinary medicine; workers involved in nuclear accident clean-up | Radiation and radionuclides |

*Monographs still in press.

†Volume and year of publication correspond to the first instance of a Group 1 classification for the agent.

‡Routes not listed for radiations and radionuclides

§The cancer sites listed reflect the most recent IARC evaluation of the agent.

¶Examples of potentially exposed industries, work locations and/or occupations described in the relevant monograph; do not represent exhaustive summaries of past and present exposure scenarios.

**Occupational and non-occupational data contributed to first Group 1 evaluation.

††Occupational data contributed to subsequent Group 1 evaluation.

IARC, International Agency for Research on Cancer; PCB, polychlorinated biphenyl; PCP, pentachloropheno; WWI, First World War.

and substance specific. The number of occupational carcinogens estimated using these criteria consequently represents a lower limit. The definition of an occupational carcinogen could be expanded to include the 12 occupations and industries with sufficient evidence in humans, the seven agents with less than sufficient evidence of carcinogenicity in humans that were upgraded to Group 1 on mechanistic grounds, or the four agents with evidence of occupational exposure but no contributing data from occupational epidemiology studies. Similarly, occupational exposures to some biological agents and pharmaceuticals have been documented elsewhere in the literature, and those with sufficient evidence in humans could be considered as occupational carcinogens.

The number of carcinogens in the workplace may be substantially larger for additional reasons. New substances are introduced into workplace and environmental settings faster than information on potential health effects can be generated. For example, over 80 000 chemicals are currently registered for use in the USA alone, but only a small fraction have ever been evaluated for carcinogenicity.¹⁵ Because of limited resources, no carcinogen evaluation programme is able to evaluate all agents of potential interest. Accordingly, the IARC Monographs give higher priority to evaluating agents for which there are indications of human exposure and scientific data suggestive of carcinogenicity. Nevertheless, among the approximately 1000 agents IARC has evaluated, the evidence on cancer in humans has been judged to be inadequate for the majority. This determination is often reached when no relevant epidemiological studies have been done, the number of studies available is too small to be conclusive, the studies are of low quality, or the findings are inconsistent across studies.

Cancer sites, agents and exposure routes

Twenty-three different types of cancer are causally associated with the 47 specific occupational carcinogens identified in this paper (table 3). Some cancers (eg, lung, urinary bladder, skin) are associated with multiple agents, and some agents are associated with more than one type of cancer. Among these, lung cancer was the most common, representing nearly a quarter (23%) of all agent-cancer associations. Other cancers that occurred frequently were skin cancer (10%), bone cancer (9%), bladder cancer (7%) and cancers of the nasal cavity and paranasal sinuses (6%) (table 3).

While the patterns of frequently occurring cancers are clear, the exact numbers are subject to interpretation because the reporting of cancer sites in the monographs necessarily depends on the data available at the time of the evaluation. Some of the tumour sites listed in table 3 could justifiably be combined, resulting in higher counts for certain cancers, such as the aggregate of tumours of lymphatic and haematopoietic tissues (9%), but with a corresponding loss of detail. The number of cancer sites associated with an agent can also increase over time if new data become available. This was the case, for example, with asbestos: the original evaluation was based only on mesothelioma and lung cancer, but cancers of the larynx and ovary have been added in subsequent evaluations.¹⁶

Patterns relating the type of agent, routes of exposure and occurrence of cancer by organ site are also evident. Inhalation and skin absorption are the principal routes of exposure for most cancer sites (table 2). Not surprisingly, inhaled agents are associated primarily with lung, nasal and sinus cancers (figure 2).

Chemicals are associated with a diverse array of cancer sites, again with inhalation and skin absorption representing

Table 3 Cancers caused by occupational carcinogens (n=47 agents), evaluated in IARC Monographs volumes 1–120

| Cancers with sufficient evidence in humans | Agents | Number of occurrences | % |
|---|---|-----------------------|-----|
| Lung | Bis(chloromethyl)ether; chloromethyl methyl ether (technical -grade); Coal-tar pitch; Sulfur mustard; Arsenic and inorganic arsenic compounds; Beryllium and beryllium compounds; Cadmium and cadmium compounds; Chromium (VI) compounds; Nickel compounds; Asbestos (all forms, including actinolite, amosite, anthophyllite, chrysotile, crocidolite, tremolite); Particulate matter in outdoor air pollution; Silica dust, crystalline, in the form of quartz or cristobalite; Soot; Welding fumes; Engine exhaust, diesel; Outdoor air pollution; Tobacco smoke, secondhand; X-radiation and Gamma-Radiation; Plutonium; Radon-222 and its decay products | 19 | 23 |
| Skin | Coal-tar pitch; Mineral oils, untreated or mildly treated; Shale oils; Arsenic and inorganic arsenic compounds; Soot; X-radiation and Gamma-Radiation; Solar radiation; Ultraviolet radiation | 8 | 10 |
| Bone, including mastoid process | X-radiation and Gamma-Radiation; Plutonium; Radium-224 and its decay products; Radium-226 and its decay products | 5 | 6 |
| Haematolymphatic system, including leukaemia, NHL | 1,3-Butadiene; Benzene; Coal-tar pitch; X-radiation and Gamma-Radiation; Formaldehyde; Lindane; Pentachlorophenol | 7 | 9 |
| Leukaemia | Benzene; Coal-tar pitch; X-radiation and Gamma-Radiation | 3 | 4 |
| Non-Hodgkin lymphoma | Formaldehyde; Lindane; Pentachlorophenol | 3 | 4 |
| Urinary bladder | <i>ortho</i> -Toluidine; Arsenic and inorganic arsenic compounds; X-radiation and Gamma-Radiation; 2-Naphthylamine; 4-Aminobiphenyl; Benzidine | 6 | 7 |
| Nasal cavity and paranasal sinus | Acid mists, strong inorganic; Chromium (VI) compounds; Leather dust; Nickel compounds; Wood dust | 5 | 6 |
| Thyroid | X-radiation and Gamma-Radiation; Radioiodines, including iodine-131 | 2 | 2 |
| Breast | X-radiation and Gamma-Radiation | 1 | 1 |
| Kidney | Trichloroethylene; X-radiation and Gamma-Radiation | 2 | 2 |
| Larynx | Asbestos (all forms, including actinolite, amosite, anthophyllite, chrysotile, crocidolite, tremolite); Acid mists, strong inorganic | 2 | 2 |
| Liver | Plutonium; Vinyl chloride | 2 | 2 |
| Nasopharynx | Formaldehyde; Wood dust | 2 | 2 |
| All cancers combined | 2,3,7,8-Tetrachlorodibenzo- <i>para</i> -dioxin | 1 | 1 |
| Biliary tract | 1,2-Dichloropropane | 1 | 1 |
| Brain and central nervous system | X-radiation and Gamma-Radiation | 1 | 1 |
| Colon | X-radiation and Gamma-Radiation | 1 | 1 |
| Esophagus | X-radiation and Gamma-Radiation | 1 | 1 |
| Eye | Ultraviolet radiation | 1 | 1 |
| Malignant melanoma | Polychlorinated biphenyls | 1 | 1 |
| Mesothelioma | Asbestos (all forms, including actinolite, amosite, anthophyllite, chrysotile, crocidolite, tremolite) | 1 | 1 |
| Ovary | Asbestos (all forms, including actinolite, amosite, anthophyllite, chrysotile, crocidolite, tremolite) | 1 | 1 |
| Salivary gland | X-radiation and Gamma-Radiation | 1 | 1 |
| Stomach | X-radiation and Gamma-Radiation | 1 | 1 |
| Total | | 82 | 100 |

IARC, International Agency for Research on Cancer; NHL, non-Hodgkin lymphoma.

the principal routes of exposure to most (table 2). Cancers frequently associated with chemicals and chemical mixtures include tumours of the lymphohaematopoietic system (25%), bladder (20%), lung (15%) and skin (15%). The aggregate of cancers of the haematopoietic and lymphatic systems, including leukaemias and non-Hodgkin's lymphomas, is mainly associated with exposure to chemicals through inhalation or contact with skin (table 2 and figure 2). To date, most chemicals are associated with only one cancer site, with the exception of formaldehyde, associated with leukaemia and cancer of the nasopharynx. Dioxin (2,3,7,8-tetrachlorodibenzo-*para*-dioxin) is unique in being associated most consistently with all cancers combined.¹⁷

Ionising radiation and radionuclides are associated with a wide array of different cancers (table 2), reflecting the varied physical properties and biological activities of these agents. X-radiation and gamma-radiation penetrate the whole body and are associated with numerous types of cancer, while radon (an inert

gas) inhaled by underground miners causes lung cancer, and radium isotopes ingested by dial painters tend to be deposited in bones and teeth and are associated with cancer of bony tissues.¹⁸ Solar radiation and ultraviolet (UV) radiation are associated with several types of skin cancer (table 2). UV radiation generated in welding is also associated with cancer of the eye.¹⁹

We examined data for the 12 agents with 'sufficient evidence of carcinogenicity' for more than one cancer site, to identify cancers that tend to co-occur. Cancers of the lung and skin most often co-occurred together, due to exposure to coal-tar pitch, soot, arsenic and inorganic arsenic compounds. A similar examination of agents associated with cancers with both sufficient and limited evidence revealed combinations for cancers of the lung and bladder or kidney (data not shown). These patterns in cancers associated with exposure to certain carcinogens may be explained by route of exposure and physiochemical properties of the agents.




Figure 2 Route of exposure to occupational carcinogens and the cancers they cause (ionising radiation not included due to the diversity of exposure routes and cancer types). NHL, non-Hodgkin lymphoma.

Trends

A comparison of [table 2](#) with previously published lists of occupational carcinogens suggests that progress continues to be made in identifying these agents despite the lack of adequate epidemiologic data for many occupational exposures. Furthermore, despite methodological differences in approach and changes in classification practices, the pace of identification appears to have increased over time. The list of 28 known occupational carcinogens developed by Siemiatycki *et al*⁹ included 12 more agents than the list of 16 occupational carcinogens identified 23 years earlier by Doll and Peto.³ [Table 2](#) of this paper includes 24 more agents added in the 14 years since Siemiatycki *et al* published their list.

Some methodological differences between reports are worth noting, however. Siemiatycki *et al*⁹ combined all ‘ionizing radiation and sources thereof’ in a single listing and include talc-containing asbestiform fibres and erionite in their counts. In contrast, we list each type of ionising radiation separately, as in the monographs, and do not include asbestiform talc or erionite, as the former is classified with asbestos and the latter did not have occupational exposure documented in the monograph.

Although neither previous authors nor we included occupations, industries or processes in the final count of occupational carcinogens (note: Siemiatycki *et al* listed them in a separate table),⁹ it is noteworthy that the occurrence of such evaluations has declined over time. A few such Group 1 evaluations have been refined or superseded by evaluations of specific agents as improved exposure data have become available: the historical evaluation of ‘boot and shoe manufacturing and repair’ has been superseded by benzene and leather dust, ‘furniture and cabinet making’ has been replaced by wood dust and haematite mining has been made more specific by the addition of ‘underground, with exposure to radon.’ In contrast, only one new Group 1 classification of an occupation, industry or process (occupational

exposures in the Acheson process for producing silicon carbide) has been added since 1989.

Improvements in the quality of epidemiologic studies may be a contributing factor in the increasing specificity of evaluations and the growth of knowledge about occupational carcinogens.²⁰ Interest in identifying subtle risks, sometimes associated with low levels of exposure, has led to increasing emphasis on obtaining quantitative or semiquantitative exposure data. The presentation of exposure-response data can be taken as one marker of study quality because it requires collection of quantitative exposure data. Furthermore, analyses of exposure-response associations internal to an occupational cohort are also less susceptible to confounding and bias than comparisons to an external referent population. Exposure-response data were noted in the pertinent monographs for 29 occupational carcinogens ([table 2](#)), most from more recent evaluations from 2010 onwards. This trend may continue if efforts to collect and retain quantitative exposure data in occupational settings are successful.²¹

The growth and diversity of available scientific information may also contribute to the increasing numbers of occupational carcinogens identified. Bibliometric research shows that the number of published scientific articles, including medical and health sciences articles, has increased exponentially since Doll and Peto’s³ work was published.²² At the same time, science is becoming more global, with growing numbers of publications from outside the historical centres of Europe, the USA and Japan.²³ Similar analyses of publications related to occupational health are not available, but statistics from the journal *Occupational & Environmental Medicine* suggest substantial growth and globalisation in this field, as well.²⁴ Studies from diverse regions of the world are valuable for hazard identification, because they can support findings of causality by demonstrating consistency across populations and locations.²⁵

There are signs for concern amid this growth, however. Some data indicate that since the 1990s, funding for occupational research has slowed or even declined in some high-income countries.^{23–26} Furthermore, significant gaps in knowledge remain concerning occupational exposures and diseases in low/middle-income countries where high exposures to many agents (which facilitate hazard identification) now tend to occur as a result of globalisation and the export of hazardous industries.^{27–28} For instance, in the People's Republic of China, coke production increased more than fivefold between 1970 and 1995, while decreasing in Europe and North America.²⁹ In several African countries, rapid developments in agricultural production have led to increased pesticide use, with implications for both occupational exposure and health.^{30–31}

CONCLUSIONS

Studies of workers have played a central role in identifying the causes of human cancer. Data compiled from the IARC Monographs from its initiation in 1971 through 2017 indicate that the number of recognised occupational carcinogens has increased progressively in recent decades. This trend may have been facilitated by advances in study quality, notably in quantitative exposure assessment, and in the global growth of the scientific literature base.

Despite notable progress, there continues to be a need for research on the causes of work-related cancer. Epidemiologic evidence is inadequate or entirely lacking for the majority of the over 1000 agents evaluated by IARC; many more agents present in workplaces have never been evaluated for carcinogenicity. There is also a need to identify the numbers of exposed workers by geographic location and to produce quantitative exposure data as a basis for hazard identification, exposure-response estimation and risk assessment.

Contributors DL conceived the paper and wrote the first draft. NG did data analyses. ALH compiled exposure data. All authors contributed to generating and reviewing the data, producing tables and figures and revising the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Brown JR, Thornton JL. Percivall Pott (1714–1788) and chimney sweepers' cancer of the scrotum. *Br J Ind Med* 1957;14:68–70.
- Cogliano VJ. Identifying carcinogenic agents in the workplace and environment. *Lancet Oncol* 2010;11:602.
- Doll R, Peto R. *The causes of cancer*. Oxford, UK: Oxford University Press, 1981.
- Checkoway H, Pearce N, Kriebel D. *Research methods in occupational epidemiology*. 2nd Ed. New York: Oxford University Press, 2004;5.
- Tomatis L. *Cancer: occurrence, causes and control*. IARC Sci Publ, 1990;100:1–11.
- Lynge E. From cross-sectional survey to cohort study. *Occup Environ Med* 2009;66:428–9.
- Afshin A, Abajobir AA, Abate KH, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1345–422.
- Takala J. Eliminating occupational cancer. *Ind Health* 2015;53:307–9.
- Siemiątycki J, Richardson S, Straif K, et al. Listing occupational carcinogens. *Environ Health Perspect* 2004;112:1447–59.
- IARC. *Preamble, IARC Monographs on the evaluation of carcinogenic risks to humans*. Lyon, France: IARC, 2006. <http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf>
- Smith MT, Guyton KZ, Gibbons CF, et al. Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis. *Environ Health Perspect* 2016;124:713–21.
- Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. *J Natl Cancer Inst* 2011;103:1827–39.
- IARC. Agents classified by the IARC Monographs volumes 1–120. 2017 <http://monographs.iarc.fr/ENG/Classification/index.php> (accessed 19 Mar 2018).
- NIOSH (National Institute for Occupational Safety and Health). NIOSH pocket guide to chemical hazards. 2017 <https://www.cdc.gov/niosh/npg/default.html>
- Wilson MP, Schwarzman MR. Toward a new U.S. chemicals policy: rebuilding the foundation to advance new science, green chemistry, and environmental health. *Environ Health Perspect* 2009;117:1202–9.
- IARC. *A Review of Human Carcinogens, Part C: Arsenic, metals, fibres and dusts*. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 100C, 2012a.
- IARC. *A Review of Human Carcinogens, Part F: Chemical agents and related occupations*. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 100F, 2012b.
- IARC. *A Review of Human Carcinogens, Part D: Radiation*. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 100D, 2012c.
- Guha N, Loomis D, Guyton KZ, et al. Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide. *Lancet Oncol* 2017;18:581–2.
- Loomis D. On the importance of quantification. *Occup Environ Med* 2012;69:609.
- Kromhout H. Hygiene Without Numbers. *Ann Occup Hyg* 2016;60:403–4.
- Bornmann L, Mutz R. Growth rates of modern science: a bibliometric analysis based on the number of publications and cited references. *J Assoc Inf Sci Technol* 2015;66:2215–22.
- Society R. Knowledge, Networks and Nations: Global scientific collaboration in the 21st century. *The Royal Society, London* 2011.
- Loomis D, Sim MR. 2012: the year in review. *Occup Environ Med* 2013;70:287–8.
- Hill AB. The environment and disease: association or causation? *Proc R Soc Med* 1965;58:295–300.
- Mabe M, Amin M. Growth dynamics of scholarly and scientific journals. *Scientometrics* 2001;2001:147–62.
- Jeyaratnam J, et al. Transfer of hazardous industries. In: Pearce N, Matos E, Vainio H, Boffetta P, Kogevinas M, . *Occupational cancer in developing countries*. IARC Sci Publ, 1994;129:23–9.
- Lucchini RG, Landon L. Global occupational health: current challenges and the need for urgent action. *Ann Glob Health* 2014;80:251–6.
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. *Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures*. Lyon, France: IARC, 2010;92.
- Ahouangninou C, Martin T, Edoth P, et al. Characterization of health and environmental risks of pesticide use in market-gardening in the Rural City of Tori-Bossito in Benin, West Africa. *J Environ Prot* 2012;03:241–8.
- Negatu B, Kromhout H, Mekonnen Y, et al. Use of Chemical Pesticides in Ethiopia: A Cross-Sectional Comparative Study on Knowledge, Attitude and Practice of Farmers and Farm Workers in Three Farming Systems. *Ann Occup Hyg* 2016;60:551–66.